EMD Millipore has been contracted to supply raw materials to the Samsung Biologics plant where ingredients for BM-S’ anticancer monoclonal antibody Yervoy (ipilimumab) are made.
As the number of drug approvals declined between 2012 and 2013 by more than 30%, the value of new therapeutic agent approvals seems to indicate a stronger year than initially thought.
Biogen Idec’s five-year deal is the latest example of biopharma embracing the strategic partnership model, but the choice of Quintiles is somewhat of a surprise, according to ISI analyst Ross Muken.
Much of the $91bn (€66bn) raised in biotech capital over the last twelve months will end up in the hands of the CRO industry, according to a survey from analyst firm Jeffries.
in-PharmaTechnologist presents its weekly round-up of the latest changes on the pharmaceutical career ladder, including news from Sirona, Hospira, and Biogen Idec.
Amgen has partnered with non-branded drugmaker Watson to develop biosimilar cancer drugs in a deal that goes some way towards protecting its own portfolio from generic competition.
Samsung will set up a $300m biosimilars development JV with Massachusetts, US-based Biogen Idec, building on the partnership it forged with CRO Quintiles earlier this year.
Outsourcing-Pharma presents its weekly round-up of the latest happenings in the world of pharmaceutical employment, including news from Genzyme, Catalent and Futura.
Outsourcing-Pharma presents its round-up of the latest movements within the pharmaceutical industry, including news from Spectrum, ProtAffin AG, Biogen Idec, and Prosonix.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including a new CEO at Patheon and appointments at Aesica.
Apricus Biosciences, formerly NexMed, announce preclinical data shows NexACT technology enables rectal delivery of biologics, including human antibodies.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including a reshuffle at PhRMA and manoeuvring of directors at OSI Pharmaceuticals and Biogen Idec.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including Genzyme strengthening its quality team and appointments at ISPE and Biogen Idec.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including the retirement of Biogen Idec’s CEO and appointments at Dishman and Noven.
The FDA has approved Biogen Idec to manufacture Tysabri using a high titre process but the product’s sales have been “negatively impacted” by the cases of patients developing PML.
Irish drugmaker Elan, which recently dropped plans to sell its Elan Drug Technologies operation, has announced job cuts and the closure of offices in a bid to save cash.
As more and more delivery firms set their sights on the specialty pharma sector, existing specialty players are increasingly abandoning established licensing strategies in favour of developing drugs in-house to compete.
Pharmaceutical company Enzon may hive off its entire specialty drugs division, including a manufacturing facility in Indianapolis, US, in the face of pressure from shareholder Carl Icahn.
Big pharma's lust for biotech's pipelines appears to be continuing
unabated with a record $27bn-worth of acquisitions and licensing
deals being made last year.
Like countless pets after every Christmas, it seems that nobody
wanted Biogen Idec after all; the firm has announced it will remain
independent after it 'did not receive any definitive offers to
purchase the company'.
Biogen Idec has announced it is seeking a buyer for the company and
has already received several expressions of interest - including a
reputed $23bn (€16.2bn) bid from billionaire corporate raider Carl
Icahn.
Biogen Idec has bagged two new partnerships in the past week which
will see it involved in the search for new drugs for central
nervous system (CNS) and inflammatory ailments.
Investment mogul Carl Icahn could get ready to buy further shares
of biotech company Biogen Idec after getting the green light from
the competition regulators.
A team of scientists at Biogen Idec have unveiled preclinical data
for a potential protein therapeutic to treat Alzheimer's, a disease
normally only attacked using small molecules due to delivery
issues.
Serono has announced a mixed third quarter 2005 with product sales
and total revenues weaker than predicted. Its net income beat
market consensus but the company was hit by an $18.3 million (€15.2
million) one-off charge related to...
US biotechnology company Biogen Idec has succumbed to the effects
of having to withdraw its multiple sclerosis drug Tysabri
(natalizumab) earlier this year, cutting 17 per cent of its
workforce and putting manufacturing facilities...
Lonza has started a SF 14 million (€9m) expansion of its biologics
manufacturing facility in Slough, UK, in response to what it said
was increasing demand for mammalian cell production for clinical
trials, reports Phil Taylor.
US biotechnology company Biogen Idec has said that it plans to sell
a California manufacturing plant built to produce its withdrawn
multiple sclerosis drug Tysabri (natalizumab) to Genentech,
reports Phil Taylor.
Ireland's largest home grown pharmaceutical company, Elan Holdings,
could be split up into two separate units, one focussing on
biotechnology and the other on manufacturing and drug delivery,
according to UK news reports.
The first in a completely new class of drug for multiple sclerosis
has been approved in the US, opening up a new avenue of treatment
for sufferers of the debilitating diseases and potential
blockbuster revenues for developers Elan...
KS Biomedix has confirmed that it is in negotiations that may lead
to a merger and add to the mini-wave of consolidation sweeping over
the UK industry.
The resurgence of merger and acquisition activity in the biotech
industry shows little sign of letting up, with US companies IDEC
Pharmaceuticals and Biogen the latest to step up to the altar
